See more : Harfang Exploration Inc. (HAR.V) Income Statement Analysis – Financial Results
Complete financial analysis of Puma Biotechnology, Inc. (PBYI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Puma Biotechnology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- NARUMIYA INTERNATIONAL Co., Ltd. (9275.T) Income Statement Analysis – Financial Results
- Kainantu Resources Ltd. (KRL.V) Income Statement Analysis – Financial Results
- Napco Security Technologies, Inc. (NSSC) Income Statement Analysis – Financial Results
- Stable Road Acquisition Corp. (SRAC) Income Statement Analysis – Financial Results
- Senior plc (SNR.L) Income Statement Analysis – Financial Results
Puma Biotechnology, Inc. (PBYI)
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 235.64M | 228.00M | 253.20M | 225.10M | 272.30M | 251.00M | 27.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -281.10K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 62.68M | 55.10M | 63.70M | 39.40M | 36.80M | 34.60M | 5.60M | 1.15M | 776.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 172.96M | 172.90M | 189.50M | 185.70M | 235.50M | 216.40M | 22.10M | -1.15M | -776.00K | 0.00 | 0.00 | 0.00 | -281.10K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 73.40% | 75.83% | 74.84% | 82.50% | 86.49% | 86.22% | 79.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 50.38M | 52.20M | 71.90M | 97.70M | 132.90M | 164.90M | 207.80M | 222.80M | 208.50M | 122.90M | 45.05M | 49.60M | 826.37K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 88.43M | 89.98M | 116.29M | 118.49M | 140.51M | 146.19M | 106.70M | 53.80M | 31.80M | 19.40M | 9.79M | 24.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 881.00K | 22.00K | 6.00K | -88.00K | 1.19M | 12.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 89.31M | 90.00M | 116.30M | 118.40M | 141.70M | 146.20M | 106.70M | 53.80M | 31.80M | 19.40M | 9.79M | 24.80M | 9.32M | 15.98K | 16.84K | 14.08K | 0.00 |
| Other Expenses | 625.00K | -28.00K | 300.00K | 400.00K | 200.00K | -9.70M | -100.00K | -400.00K | 25.00K | -14.00K | 2.00K | 293.00K | 10.70K | 0.00 | 0.00 | 0.00 | -15.09M |
| Operating Expenses | 140.32M | 142.20M | 188.20M | 216.10M | 274.60M | 311.10M | 314.50M | 276.60M | 240.30M | 142.30M | 54.83M | 74.40M | 10.16M | 15.98K | 16.84K | 14.08K | -15.09M |
| Cost & Expenses | 203.00M | 197.30M | 251.90M | 255.50M | 311.40M | 345.70M | 320.10M | 276.60M | 240.30M | 142.30M | 54.83M | 74.40M | 10.16M | 15.98K | 16.84K | 14.08K | -15.09M |
| Interest Income | 2.61M | 800.00K | 100.00K | 500.00K | 2.80M | 1.80M | 1.20M | 1.00M | 1.00M | 300.00K | 172.00K | 100.00K | 3.78K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 13.33M | 11.50M | 12.80M | 14.10M | 15.00M | 11.00M | 700.00K | 958.00K | 971.00K | 324.00K | 172.00K | 98.00K | 3.78K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 11.52M | 8.92M | 10.60M | 7.20M | 4.80M | 7.38M | 2.81M | 1.15M | 776.00K | 627.00K | 423.00K | 265.00K | 10.70K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | 47.52M | 20.97M | -5.40M | -38.54M | -55.72M | -95.21M | -288.42M | -275.45M | -239.50M | -141.65M | -54.41M | -74.09M | -10.22M | -15.98K | -16.84K | -14.08K | -15.09M |
| EBITDA Ratio | 20.17% | 13.82% | 0.67% | -13.11% | -13.26% | -40.88% | -1,051.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,580.97% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 32.64M | 23.70M | -8.90M | -30.40M | -39.10M | -94.70M | -292.40M | -276.60M | -240.30M | -142.30M | -54.83M | -74.40M | -10.16M | -15.98K | -16.84K | -14.08K | -15.09M |
| Operating Income Ratio | 13.85% | 10.39% | -3.51% | -13.51% | -14.36% | -37.73% | -1,055.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,613.24% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -9.97M | -23.26M | -30.09M | -29.39M | 53.00K | -18.92M | 435.00K | 585.00K | 996.00K | 310.00K | 174.00K | 98.00K | -76.22K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 22.67M | 500.00K | -28.80M | -59.80M | -75.60M | -113.60M | -292.00M | -276.00M | -239.30M | -142.00M | -54.66M | -74.30M | -10.23M | -15.98K | -16.84K | -14.08K | -15.09M |
| Income Before Tax Ratio | 9.62% | 0.22% | -11.37% | -26.57% | -27.76% | -45.26% | -1,054.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,640.35% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.08M | 500.00K | 300.00K | 200.00K | 7.12M | -7.92M | -2.21M | -2.15M | -1.75M | -941.00K | -172.00K | -267.00K | 76.22K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 21.59M | 912.00K | -29.10M | -60.00M | -82.72M | -113.60M | -292.00M | -276.00M | -239.30M | -142.00M | -54.66M | -74.30M | -10.23M | -15.98K | -16.84K | -14.08K | -15.09M |
| Net Income Ratio | 9.16% | 0.40% | -11.49% | -26.65% | -30.38% | -45.26% | -1,054.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,640.35% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.46 | 0.02 | -0.72 | -1.52 | -2.13 | -2.99 | -7.86 | -8.29 | -7.45 | -4.73 | -1.90 | -3.42 | -0.51 | 0.00 | -0.01 | 0.00 | -0.38 |
| EPS Diluted | 0.45 | 0.02 | -0.72 | -1.52 | -2.13 | -2.99 | -7.86 | -8.29 | -7.45 | -4.73 | -1.90 | -3.42 | -0.51 | 0.00 | -0.01 | 0.00 | -0.38 |
| Weighted Avg Shares Out | 47.13M | 44.67M | 40.64M | 39.58M | 38.77M | 37.94M | 37.17M | 33.30M | 32.13M | 30.01M | 28.70M | 21.73M | 20.04M | 7.75M | 3.00M | 3.00M | 39.29M |
| Weighted Avg Shares Out (Dil) | 47.55M | 44.93M | 40.64M | 39.58M | 38.77M | 37.94M | 37.17M | 33.30M | 32.13M | 30.01M | 28.70M | 21.73M | 20.04M | 7.75M | 3.00M | 3.00M | 39.29M |
Puma Biotech (PBYI) Reports Q2 Loss, Tops Revenue Estimates
Puma Biotech (PBYI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to earnings of $0.10 per share a year ago.
Puma Biotechnology Reports Second Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued its second quarter financial results and hosted a conference call on August 1, 2024.
Bet on These 4 Top-Performing Liquid Stocks for Solid Gains
Liquidity indicates a company's capability to meet debt obligations by converting its assets into liquid cash and equivalents.
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results
LOS ANGELES--(BUSINESS WIRE)--On Aug. 1, Puma Biotechnology will issue its earnings results for the 2024 second quarter and follow with a conference call to discuss the results.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology granted an inducement award to one new employee, who was hired in June 2024.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 6, 2024, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit award covering 3,500 shares of Puma common...
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology Announced Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer at the 2024 ASCO Annual Meeting.
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that findings from the Phase II trial of its drug alisertib (TBCRC 041) were presented at the ASCO 2024 Annual Meeting.
Puma Biotechnology to Join Russell 3000 Index
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology is on the preliminary list of additions to the Russell 3000 Index.
Source: https://incomestatements.info
Category: Stock Reports